186 related articles for article (PubMed ID: 11840417)
1. Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).
Bookman MA
Semin Oncol; 2002 Feb; 29(1 Suppl 1):20-31. PubMed ID: 11840417
[TBL] [Abstract][Full Text] [Related]
2. Developmental chemotherapy and management of recurrent ovarian cancer.
Bookman MA
J Clin Oncol; 2003 May; 21(10 Suppl):149s-167s. PubMed ID: 17633784
[TBL] [Abstract][Full Text] [Related]
3. Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group.
Bookman MA
Int J Gynecol Cancer; 2001; 11 Suppl 1():42-51. PubMed ID: 11489003
[TBL] [Abstract][Full Text] [Related]
4. The role of gemcitabine-based doublets in the management of ovarian carcinoma.
Thigpen T
Semin Oncol; 2002 Feb; 29(1 Suppl 1):11-6. PubMed ID: 11840415
[TBL] [Abstract][Full Text] [Related]
5. Future directions in the chemotherapy of ovarian cancer.
Ozols RF
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5.
Copeland LJ; Bookman M; Trimble E;
Gynecol Oncol; 2003 Aug; 90(2 Pt 2):S1-7. PubMed ID: 12927999
[TBL] [Abstract][Full Text] [Related]
7. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced ovarian cancer.
du Bois A
Eur J Cancer; 2001 Dec; 37 Suppl 9():S1-7. PubMed ID: 11741767
[TBL] [Abstract][Full Text] [Related]
9. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
Bookman MA; Brady MF; McGuire WP; Harper PG; Alberts DS; Friedlander M; Colombo N; Fowler JM; Argenta PA; De Geest K; Mutch DG; Burger RA; Swart AM; Trimble EL; Accario-Winslow C; Roth LM
J Clin Oncol; 2009 Mar; 27(9):1419-25. PubMed ID: 19224846
[TBL] [Abstract][Full Text] [Related]
11. Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
Tian C; Ambrosone CB; Darcy KM; Krivak TC; Armstrong DK; Bookman MA; Davis W; Zhao H; Moysich K; Gallion H; DeLoia JA
Gynecol Oncol; 2012 Mar; 124(3):575-81. PubMed ID: 22112610
[TBL] [Abstract][Full Text] [Related]
12. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma.
Hansen SW
Semin Oncol; 2002 Feb; 29(1 Suppl 1):17-9. PubMed ID: 11840416
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin versus cisplatin in ovarian cancer.
Alberts DS
Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
[TBL] [Abstract][Full Text] [Related]
16. Optimizing gemcitabine regimens in ovarian cancer.
Pecorelli S; Pasinetti B; Tisi G; Odicino F
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S17-25. PubMed ID: 16716799
[TBL] [Abstract][Full Text] [Related]
17. Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
Krivak TC; Darcy KM; Tian C; Bookman M; Gallion H; Ambrosone CB; Deloia JA
Gynecol Oncol; 2011 Jul; 122(1):121-6. PubMed ID: 21496891
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
19. The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
Thigpen T
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S26-32. PubMed ID: 16716800
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
Ozols RF
Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
